iShares Russell 2000 ETF (IWM)

The company said that its fourth quarter 2025 net income was $40 million, or $0.23 per share, compared to a net loss of $68 million, or $0.40 per share in 2024.

SELLAS is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia who have achieved complete remission following second-line salvage therapy.

The plant-based meat company added four flavors to its beverage lineup on Thursday.

H.C. Wainwright sees risks associated with Mara's pronounced pivot to AI and hyperscale data centers.

The company reported a 34% jump in fourth-quarter revenue to $134.3 million, beating Wall Street’s estimates of $128.2 million, according to Fiscal.ai data.

MARA Holdings announced it has entered into a strategic agreement with Starwood Capital Group and their dedicated data center development platform Starwood Digital Ventures.

WASHINGTON D.C. — In a significant endorsement of the Federal Reserve’s current monetary trajectory, International Monetary Fund (IMF) Managing Director Kristalina Georgieva stated on February 26, 2026, that the U.S. central bank has sufficient room to lower interest rates to approximately 3.4% from the current effective level

The financial landscape of early 2026 has been defined by a definitive "Great Rotation," as investors aggressively pivot away from the mega-cap technology giants that dominated the previous decade in favor of long-neglected small-cap stocks. In a dramatic reversal of the "Magnificent Seven" era, the Russell 2000 Index (NYSE: IWM)

The company stated that its technology powers the Romanian National Quantum Communication Infrastructure, one of the largest quantum key distribution networks outside of China.

Array’s Q4 revenue fell 17% year-on-year to $226 million, while net loss widened to $145.7 million.

Aurinia reported adjusted earnings per share of $1.53 on revenue of $77.1 million, while Wall Street analysts expected an adjusted EPS of $0.22 on revenue of $74.7 million, according to Koyfin data.

Recursion reported a loss of $0.21 per share on revenue of $35.5 million, compared to Wall Street estimates of a loss of $0.32 per share on revenue of $24.6 million, according to Koyfin.

Analysts expect the company to post higher fourth quarter revenue than the year-ago quarter, as per data from fiscal.ai.

This healthcare firm delivers surgical solutions for peripheral nerve repair, targeting specialized surgeons across U.S. and global markets.

Cipher’s fourth-quarter revenue came in at $60 million, significantly below the consensus estimates of $85.7 million, according to Fiscal.ai data.

TD Cowen analyst Joseph Thome’s new price target represents a potential upside of about 23% from AXSM’s current trading levels.

Bitdeer said on Monday that it plans to keep mining Bitcoin and anticipates that its hash rate will continue to grow.

The company is seeking approval for Molbreevi to treat patients with Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP).

This is the second Vanda drug to be approved in the span of a few months, after the approval of Nereus in December.

Analysts at H.C. Wainwright hiked their price target for Ardelyx shares to $18 from $10.

The company also announced the establishment of an Irish subsidiary in Dublin to support its distribution and commercialization strategy across Europe.

Lemonade reported a 31% year-on-year growth in In Force Premium to $1.24 billion in the fourth quarter.